Biomea Fusion, Inc.
HealthcareNASDAQ:BMEA · NASDAQ Global Select
-$0.02 today
Vol 0.61M · Avg 1.55M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-209.1%
avg 708.0%
ROIC
-166.2%
avg 729.7%
ROA
-105.5%
avg -126.2%
Analysis
ROA is currently the strongest return metric at -105.5% versus its period average of -126.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael J. Hitchcock | Interim Chief Executive Officer & Director | $867,935.00 | — | 76 | $667,477.00 | 1.12% |
Ramses Erdtmann | Co-Founder, President, Chief Operating Officer & Director | $636,485.00 | — | 63 | $452,512.00 | 0.76% |
Caroline Perez- Dupont | Senior Vice President of Legal | — | — | — | — | — |
Heow Tan | Chief Technology & Quality Officer | — | — | 67 | — | — |
Stephan Morris | Chief Development Officer | — | — | — | — | — |
Ravi Upasani | Executive Vice President of Intellectual Property | — | — | — | — | — |
Thorsten Kirschberg | Executive Vice President of Research | — | — | 56 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$196,731.00
Sells
0
$0.00
Net Sentiment
+$196,731.00
Net buying
Most Active
Erdtmann Rainer M
3 transactions
Analysis
Insiders reported 4 buys worth $196,731.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $196,731.00. Erdtmann Rainer M was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.70M
ALX Oncology Holdings Inc.
NASDAQ:ALXO
$212.61M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$155.81M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Repare Therapeutics Inc.
RPTX
$114.24M
Adverum Biotechnologies, Inc.
ADVM
$96.26M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$89.00M
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
$61.36M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Cibus, Inc.
NASDAQ:CBUS
$55.95M
Who manages BMEA?
Biomea Fusion, Inc. (BMEA) lists 7 active executives. The top listed executive is Caroline Perez- Dupont, Senior Vice President of Legal.
Are BMEA insiders buying or selling?
Recent insider activity shows net buying of $49.11M.
Explore More
Continue the stock analysis
Jump to another research area for this company.